13 June 2024

BSF Enterprise PLC

("BSF" or the "Company")

Grant of Options

BSF (LSE: BSFA), (OTCQB: BSFAF), a UK listed biotech company and owner of pioneering UK-based tissue engineering company, 3D Bio-Tissues (3DBT), and corneal replacement company, Kerato, announces a grant of Enterprise Management Incentive options ("Options") over new ordinary shares at an exercise price of 15 pence each in the Company ("Ordinary Shares").

Options have been granted in respect of a total of 2,400,000 new Ordinary Shares to employees of BSF and its subsidiaries. These new Options represent, in aggregate, 2.23 per cent of the Company's current issued share capital.

The Options are exercisable at 15 pence per Ordinary Share. Of these Options, 1,650,000 will vest on  the 2nd anniversary of the date of grant and 750,000 options will vest on the 3rd anniversary of the date of grant.  

An Option may be exercised from the third anniversary of the Date of Grant. An Option shall not be exercisable more than ten years after the Date of Grant.

Following the Options grant, the Company will have a total of 2,400,000 options over Ordinary Shares in issue.

For further enquiries, please visit www.bsfenterprise.com or contact:

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions to deliver sustainable materials and products across a variety of sectors. BSF Enterprise's core technology platform in industrial tissue engineering allows the manufacture at scale of lab-grown alternatives to animal and human tissues, helping deliver sustainable products and materials of the future. The Company's technologies have multiple applications across consumer and medical markets including lab-grown leather, cultivated meat, human corneas and in vitro animal models.

BSF owns 100% of pioneering UK-based tissue engineering companies 3D Bio-Tissues (3DBT), that successfully produced the UK's first high-quality cultivated meat and lab-grown skin from its laboratory and Kerato, a developer of lab-grown corneal replacement tissue for medical and research uses. In addition, it owns 100% of BSF Enterprise (Hong Kong) Limited which is actively supporting commercialisation of our technology in China and Asia.

BSF aims to deliver growth to shareholders through the continued commercialisation and expansion of the Groups IP, which has multiple applications, as well as through M&A. BSF aims to build a comprehensive portfolio in tissue engineering and related applications and license out IP to various stakeholders in the supply chain to enable manufacture at scale and achieve widespread market penetration.